tickdelta
Sign in

Tickdelta is free for now. Sign up and get Pro free

← Screener

Health care · Medical Devices · NYSE

ZBHZimmer Biomet

Compare with peers → Embed
The 10-K against last year's

99 changes: 21 added, 9 removed, 67 reworded, 2 quiet changes

10-K Feb 20, 2026 vs Feb 25, 2025
Risk FactorsRedline ↓
17.1%
of the text changed · 9,933 words now
33.0%
of the text changed · 5,616 words now
Legal ProceedingsRedline ↓
42.7%
of the text changed · 646 words now
Accounting PoliciesRedline ↓
15.9%
of the text changed · 3,755 words now

10-K 0001193125-26-059853 (2026-02-20) vs 10-K 0000950170-25-026604 (2025-02-25)

The redline

The paragraph that changed most in each section

Marked against last year's 10-K: cut words struck through, new words highlighted and underlined.

Risk Factors 194 words changed in this paragraph; it is 45% similar to last year's version.
Changes in the tax laws and regulations of the jurisdictions where we do business, including an increase in tax rates or an adverse change in the treatment of an item of income or expense, could result in a material increase in our tax expense and/or tax payments, could increase tax uncertainty and could have a material adverse impact on our business, financial condition or results of operations.Tax law changes in certain foreign jurisdictions in which we operate conforming to Pillar Two of the base erosion and profit shifting plan (“Pillar Two”) undertaken by the operations. The Organisation for Economic Co-operation and Development began (OECD) has a framework to take implement a global minimum corporate tax of 15% for companies with global revenue and profits above certain thresholds (referred to as Pillar 2). Although the U.S. has not enacted legislation to implement Pillar 2, certain countries in which we operate have adopted legislation, and other countries are in the process of introducing legislation to implement Pillar 2. The OECD issued new administrative guidance on January 5, 2026, with respect to Pillar 2 which modifies key aspects of the framework for countries to enact in their own laws. It remains uncertain whether or how countries will implement Pillar 2 and the OECD administrative guidance, which may have a further adverse effect in 2024. We expect the implementation and interpretation of Pillar Two across jurisdictions where we do business to have adverse effects on our effective tax rate, results of operations, and cash flows. These tax law changes require profits earned in such jurisdictions to be subject to a minimum 15 percent income tax rate. liabilities.

Source: Item 1A, 10-K 0001193125-26-059853 vs Item 1A, 10-K 0000950170-25-026604

MD&A 161 words changed in this paragraph; it is 42% similar to last year's version.
In 2024, 2025, our net sales increased 3.8 7.2 percent when compared to 2023. 2024. Net sales growth was driven by a combination of our acquisition of Paragon 28, Inc. (“Paragon 28”) on April 21, 2025, market growth, new product introductions, positive price realization and commercial execution across lower net sales in the organization. These favorable items were negatively impacted by our transition in July 2024 prior year due to operational challenges fulfilling customer orders as a consequence of a new enterprise resource planning ("ERP") software system for implementation. Paragon 28 had a significant portion of positive impact on our U.S. and Canada sales and commercial operations. As a result of this ERP implementation, we experienced operational challenges which affected our ability to fulfill certain customer orders. This disruption mostly affected our U.S. net sales, but our International net sales were also impacted as shipments to our international affiliates were delayed. Shipping levels returned to similar levels that existed prior to the implementation by the end growth of the year. For the full year 2024, we estimate this ERP implementation had less than a one 2.5 percent impact to our net sales. in 2025. In addition, our net sales in 2024 were tempered by experienced a negative 1.0 positive effect of 0.8 percent effect from changes in foreign currency exchange rates. rates in 2025.

Source: Item 7, 10-K 0001193125-26-059853 vs Item 7, 10-K 0000950170-25-026604

Accounting Policies 84 words changed in this paragraph; it is 77% similar to last year's version.
Intangible assets with an indefinite life, including certain trademarks and trade names and in-process research and development (“IPR&D”) projects, are not amortized. Indefinite life intangible assets are assessed annually to determine whether events and circumstances continue to support an indefinite life. Intangible assets with an indefinite life are tested for impairment annually or whenever events or circumstances indicate that the fair value of the asset is more likely than not below its carrying amount. An impairment loss is recognized if the carrying amount exceeds the estimated fair value of the asset. The amount of the impairment loss to be recorded would be determined based upon the excess of the asset’s carrying value over its fair value. The fair values of indefinite lived intangible assets are determined based upon a discounted cash flow analysis using the relief from royalty method or a qualitative assessment may be performed for any changes to the asset’s fair value from the last quantitative assessment. The relief from royalty method estimates the cost savings associated with owning, rather than licensing, assets. Significant assumptions are incorporated into these discounted cash flow analyses such as estimated growth rates, royalty rates and risk-adjusted discount rates. We may do a qualitative assessment when the results of the previous quantitative test indicated that the asset’s fair value was significantly in excess of its carrying value.

Source: Item 8, Note 2 – Significant Accounting Policies, 10-K 0001193125-26-059853 vs Item 8, Note 2 – Significant Accounting Policies, 10-K 0000950170-25-026604

Legal Proceedings 11 words changed in this paragraph; it is 95% similar to last year's version.
We recognize litigation-related charges and gains in Selling, general and administrative expense on our consolidated statement of earnings. During the years ended December 31, 2024, 2025, 2024 and 2023, and 2022, we recognized $22.7 million, $30.5 million, $21.6 million and $65.9 $21.6 million, respectively, of net litigation-related charges. At December 31, 2024 2025 and 2023, 2024, accrued litigation liabilities were $156.4 $136.2 million and $244.1 $156.4 million, respectively. These litigation-related charges and accrued liabilities reflect all of our litigation-related contingencies and not just the matters discussed below. contingencies. The ultimate cost of litigation could be materially different than the amount of the current estimates and accruals and could have a material adverse impact on our financial condition and results of operations.

Source: Item 3, via Note 20 – Commitments and Contingencies, 10-K 0001193125-26-059853 vs Item 3, via Note 21 – Commitments and Contingencies, 10-K 0000950170-25-026604

Every change, by type

Sentences and paragraphs added, removed or reworded

Sentences and paragraphs of ZBH's Risk Factors and MD&A, 10-K 2026-02-20 against 10-K 2025-02-25. Each links to the text at sec.gov.

RemovedRisk Factors
demand in some instances. As a result, we may experience lost sales, which we may be unable to recover, loss of market share, which we may be unable to recapture, and/or harm to our reputation, which could adversely affect our business, financial condition and results of operations.

Read it in 10-K 2025-02-25 at sec.gov ↗

RemovedMD&A
On March 1, 2022, we completed the spinoff of our spine and dental businesses into ZimVie. The historical results of our spine and dental businesses have been reflected as discontinued operations in our consolidated financial statements in our 2022 results through the date of the spinoff. See Note 3 to our consolidated financial statements for additional information. The following discussion and analysis is presented on a continuing operations basis unless otherwise noted.

Read it in 10-K 2025-02-25 at sec.gov ↗

RemovedMD&A
Our net earnings were $903.8 million in 2024 compared to $1,024.0 million in 2023. The decline in net earnings was driven by higher favorable tax settlements in 2023 compared to 2024, higher charges from our 2023 Restructuring Plan which was instituted at the end of 2023 and continued into 2024, including $84.6 million in employee termination benefits-related charges recognized in 2024, and higher intangible asset amortization. These unfavorable items were partially offset by the net sales increase, savings from our 2023 Restructuring Plan and other initiatives, and lower research and development ("R&D") spending for initial compliance with the European Union Medical Device Regulation ("EU MDR").

Read it in 10-K 2025-02-25 at sec.gov ↗

RemovedMD&A
In the Americas, operating profit increased, but operating profit as a percentage of net sales slightly decreased, in 2024 compared to 2023. The increase in operating profit in 2024 was primarily due to higher net sales driven by market growth and new product introductions, coupled with lower royalty expense as a result of agreements we entered into in 2023 to acquire intellectual property through the buyout of certain licensing arrangements. However, operating profit as a percentage of net sales decreased slightly due to investments in instruments to support new product introductions and higher bad debt-related charges in 2024.

Read it in 10-K 2025-02-25 at sec.gov ↗

RemovedMD&A
In EMEA, operating profit and operating profit as a percentage of net sales increased in 2024 when compared to 2023. The increases were due to higher net sales driven by market growth and improved pricing, lower excess and obsolete inventory charges, reduced royalty expense as a result of agreements we entered into in 2023 to acquire intellectual property through the buyout of certain licensing arrangements, and lower expenses driven by our 2023 Restructuring Plan and cost savings initiatives.

Read it in 10-K 2025-02-25 at sec.gov ↗

RemovedMD&A
In Asia Pacific, operating profit and operating profit as a percentage of net sales increased in 2024 when compared to 2023. The increases were due to higher net sales driven by market growth and improved pricing, reduced royalty expense as a result of agreements we entered into in 2023 to acquire intellectual property through the buyout of certain licensing arrangements, and lower expenses driven by our 2023 Restructuring Plan and cost savings initiatives.

Read it in 10-K 2025-02-25 at sec.gov ↗

RemovedMD&A
In January 2025, we entered into a definitive agreement to acquire all outstanding shares of Paragon 28, Inc (“Paragon 28”). The proposed transaction will require initial consideration of approximately $1.2 billion to be paid at closing, which is expected to occur in the first half of 2025. We expect to fund the proposed transaction through a combination of cash on hand and other available debt financing sources. See Note 22 to our consolidated financial statements for additional information related to this proposed transaction.

Read it in 10-K 2025-02-25 at sec.gov ↗

Show the other 1
RemovedMD&A
In February 2025, we issued senior notes with aggregate principal amounts of $600 million of 4.700% notes due 2027 (“2027 Notes”), $550 million of 5.050% notes due 2030 (“2030 Notes”), and $600 million of 5.500% notes due 2035 (“2035 Notes”). We intend to use the net proceeds from these notes, together with cash on hand or other immediately available funds, to pay the consideration, fees, and expenses for the Paragon 28 acquisition. We further intend to use a portion of the proceeds of the 2027 Notes for general corporate purposes, which may include the repayment of other indebtedness (which could include the repayment of our 3.550% notes due April 1, 2025), share repurchases, financing capital commitments and financing future acquisitions. If we fail to consummate the Paragon 28 acquisition either (i) prior to November 28, 2025 (as such date may be extended in accordance with the terms of the Paragon 28 merger agreement and the supplemental indenture governing the 2030 Notes and the 2035 Notes); or (ii) due to the termination of Paragon 28 merger agreement pursuant to its terms, then we will be obligated to redeem all of the 2030 notes and the 2035 notes on the special mandatory redemption date at a redemption price equal to 101% of the principal amount of such series of notes, plus accrued and unpaid interest to, but excluding, the special mandatory redemption date.

Read it in 10-K 2025-02-25 at sec.gov ↗

Next Related parties →